Viatris (VTRS) posts Q3 2025 results and updates 2025 guidance

Pharmaceuticals company Viatris Inc. (NASDAQ: VTRS) on Thursday reported financial results for the third quarter of fiscal 2025, and updated its outlook for fiscal 2025. The company reported a net loss of $128 million for the third quarter, compared to net earnings of $95 million in the prior-year quarter On a per-share basis, Q3 loss […]

$VTRS November 6, 2025 1 min read

The company reported a net loss of $128 million for the third quarter, compared to net earnings of $95 million in the prior-year quarter
On a per-share basis, Q3 loss was $0.11, compared to earnings of $0.08 per share in Q3 2024
On an adjusted basis, the company reported earnings of $0.67 per share for Q3, down 11% on a reported basis and down 9% on a divestiture-adjusted operational basis
At $3.8 billion, third-quarter revenue was broadly flat year-over-year on a reported basis, and down 1% on an adjusted basis
Excluding special items, divestiture-adjusted operational total revenues increased 1% compared to last year
Viatris generated approximately $100 million in new product revenues during the quarter
Adjusted EBITDA was $1.2 billion in Q3, down 10% YoY on a reported basis and down 8% on a divestiture-adjusted operational basis
The company generated net cash provided by operating activities of $745 million and free cash flow of $658 million in Q3
The management revised its full-year revenue guidance to $13.9-14.3 billion from the earlier forecast of $13.5-$14.0 billion

Related Articles

DFIN’s Software Pivot Pays Off: High Margins and Recurring Revenue Lead the Way

Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth

Innovation and E-Commerce at the Core of Johnson Outdoors’ 2026 Roadmap